Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Генетическая предрасположенность к рецидивирующему течению вульвовагинального кандидоза
Генетическая предрасположенность к рецидивирующему течению вульвовагинального кандидоза
Погосян Ш.М., Межевитинова Е.А., Донников А.Е. и др. Генетическая предрасположенность к рецидивирующему течению вульвовагинального кандидоза. Гинекология. 2017; 19 (4): 20–25. DOI: 10.26442/2079-5696_19.4.20-25
19 (4): 20–25. DOI: 10.26442/2079-5696_19.4.20-25
________________________________________________
19 (4): 20–25. DOI: 10.26442/2079-5696_19.4.20-25
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Вульвовагинальный кандидоз (ВВК) зачастую встречается у женщин репродуктивного возраста. У 5–10% женщин ВВК развивается рецидивирующий ВВК (РВВК), который характеризуется развитием 4 и более эпизодов ВВК в течение 12 мес. Есть данные, что наряду с известными факторами риска, такими как антибактериальная терапия, сахарный диабет, беременность, в патогенезе развития РВВК важную роль принадлежит генетическим особенностям пациенток и противогрибковому иммунному ответу. Целью настоящего исследования явилось выявление молекулярно-генетических факторов рецидивирования ВВК. Результаты нашего исследования показали, что однонуклеотидный полиморфизм генов IL4, IL1b и CCL2 ассоциирован с рецидивирующим вульвовагинальным кандидозом и является предрасполагающим фактором для его развития.
Ключевые слова: вульвовагинальный кандидоз, рецидивирующий вульвовагинальный кандидоз (РВВК), предрасположенность к развитию РВВК, полиморфизм генов, генетическая факторы развития РВВК.
Key words: vulvovaginal candidiasis, recurrent vulvovaginal candidiasis (RVVC), predisposition to RVVC, gene polymorphism, genetic factors of RVVC.
Ключевые слова: вульвовагинальный кандидоз, рецидивирующий вульвовагинальный кандидоз (РВВК), предрасположенность к развитию РВВК, полиморфизм генов, генетическая факторы развития РВВК.
________________________________________________
Key words: vulvovaginal candidiasis, recurrent vulvovaginal candidiasis (RVVC), predisposition to RVVC, gene polymorphism, genetic factors of RVVC.
Полный текст
Список литературы
1. Sherrard J, Donders G, White D. European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge. European STI Guidelines Editorial Board. 2011; p. 1–23.
2. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178 (2): 203–11.
3. Foxman B, Muraglia R, Dietz J-P et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Lower Genital Tract Dis 2013; 17 (3): 340–5.
4. Sobel JD. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178 (2): 203–11.
5. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016; 214 (1): 15–21.
6. Guzel AB, Ilkit M, Burgut R et al. An Evaluation of Risk Factors in Pregnant Women with Candida Vaginitis and the Diagnostic Value of Simultaneous Vaginal and Rectal Sampling. Mycopathologia 2011; 172 (1): 25–36.
7. Mårdh P-A, Rodrigues AG, Genç M et al. Facts and myths on recurrent vulvovaginal candidosis – a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002; 13 (8): 522–39.
8. Calderon L, Williams R, Martinez M et al. Genetic susceptibility to vaginal candidiasis. Med Mycol 2003; 41 (2): 143–7.
9. Jaeger M, Plantinga TS, Joosten LAB et al. Genetic basis for recurrent vulvo-vaginal candidiasis. Cur Infect Dis Rep 2013; 15 (2): 136–42.
10. Smeekens SP. Genetic susceptibility to Candida infections. EMBO Mol Med 2013; 5 (6): 805–13.
11. Rosentul D. Polymorphism in innate immunity genes and susceptibility to recurrent vulvovaginal candidiasis. J Mycol Med 2009; 19 (3): 191–6.
12. Puel A. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012; 12 (6): 616–22.
13. Babula O, Lazdane G, Kroica J et al. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37 (5): 733–7.
14. Babula O, Lazdane G, Kroica J et al. Frequency of interleukin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40 (9): 1258–62.
15. De Luca A, Carvalho A, Cunha C et al. IL-22 and IDO1 Affect Immunity and Tolerance to Murine and Human Vaginal Candidiasis. PLoS Pathogens 2013; 9 (7).
16. Donders GGG, Babula O, Bellen G et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115 (10): 1225–31.
17. Giraldo PC, Babula O, Goncalves AK et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007; 109: 1123–8.
18. Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92 (1): 43–7.
19. Rosentul DC, Plantinga TS, Oosting M et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis 2011; 204 (7): 1138–45.
20. Ferwerda B, Ferwerda G, Plantinga TS et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361 (18): 1760–7.
21. Glocker E-O, Hennigs A, Nabavi M et al. A Homozygous CARD9 Mutation in a Family with Susceptibility to Fungal Infections. N Engl J Med 2009; 361 (18): 1727–35.
22. Nahum A. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. Autoimmun Rev 2012; 11 (5): 341–7.
23. Nahum A, Bates A, Sharfe N, Roifman CM. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 122 (6): 1220–2.
24. Brouwer N, Dolman KM, van Houdt M et al. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol 2008; 180 (6): 4124–32.
25. Neth O, Jack DL, Dodds AW et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68 (2): 688–93.
26. Sharfe N, Shahar M, Roifman CM. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. J Clin Investig 1997; 100 (12): 3036–43.
27. Practice Bulletin Clinical Management Guidelines for Obstetrician – Gynecologists. Obstet Gynecol 2009; 106: 192–202..
28. Mendling W. Guideline: Vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015; 58 (S1): 1–15.
29. Plantinga TS, Johnson MD, Scott WK et al. Human genetic susceptibility to Candida infections. Med Mycol 2012; 1–10.
30. Wójtowicz A, Tissot F, Lamoth F et al. Polymorphisms in tumor necrosis factor-a increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients. Crit Care Med 2014; 42 (4): e304–8.
31. Ouederni M, Sanal O, Ikincioqullari A et al. Clinical features of candidiasis in patients with inherited interleukin 12 receptor b1 deficiency. Clin Infect Dis 2014; 58 (2): 204–13.
32. Naglik JR. Candida Immunity. New J Sci 2014; 2014 (Article ID 390241).
33. Choi EH, Foster CB, Taylor JG et al. Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J Infect Dis 2003; 187 (7): 1153–6.
34. Corbett JA, Kwon G, Turk J, McDaniel ML. IL-1b induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of langerhans: Activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32 (50): 13767–70.
35. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nature reviews. Microbiology 2004; 2 (10): 820–32.
36. Johnson MD, Plantinga TS, Van De Vosse E et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: A prospective cohort study. Clin Infect Dis 2012; 54 (4): 502–10.
37. Rosentul DC, Delsing CE, Jaeger M et al. Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Front Microbiol 2014; 5: 483.
38. Sun R, Tian W, Xing X. Association of cytokine gene polymorphisms with susceptibility to invasive candidiasis. Genet Mol Res 2015; 14 (142): 6859–64.
2. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178 (2): 203–11.
3. Foxman B, Muraglia R, Dietz J-P et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Lower Genital Tract Dis 2013; 17 (3): 340–5.
4. Sobel JD. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178 (2): 203–11.
5. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016; 214 (1): 15–21.
6. Guzel AB, Ilkit M, Burgut R et al. An Evaluation of Risk Factors in Pregnant Women with Candida Vaginitis and the Diagnostic Value of Simultaneous Vaginal and Rectal Sampling. Mycopathologia 2011; 172 (1): 25–36.
7. Mårdh P-A, Rodrigues AG, Genç M et al. Facts and myths on recurrent vulvovaginal candidosis – a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002; 13 (8): 522–39.
8. Calderon L, Williams R, Martinez M et al. Genetic susceptibility to vaginal candidiasis. Med Mycol 2003; 41 (2): 143–7.
9. Jaeger M, Plantinga TS, Joosten LAB et al. Genetic basis for recurrent vulvo-vaginal candidiasis. Cur Infect Dis Rep 2013; 15 (2): 136–42.
10. Smeekens SP. Genetic susceptibility to Candida infections. EMBO Mol Med 2013; 5 (6): 805–13.
11. Rosentul D. Polymorphism in innate immunity genes and susceptibility to recurrent vulvovaginal candidiasis. J Mycol Med 2009; 19 (3): 191–6.
12. Puel A. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012; 12 (6): 616–22.
13. Babula O, Lazdane G, Kroica J et al. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37 (5): 733–7.
14. Babula O, Lazdane G, Kroica J et al. Frequency of interleukin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40 (9): 1258–62.
15. De Luca A, Carvalho A, Cunha C et al. IL-22 and IDO1 Affect Immunity and Tolerance to Murine and Human Vaginal Candidiasis. PLoS Pathogens 2013; 9 (7).
16. Donders GGG, Babula O, Bellen G et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115 (10): 1225–31.
17. Giraldo PC, Babula O, Goncalves AK et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007; 109: 1123–8.
18. Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92 (1): 43–7.
19. Rosentul DC, Plantinga TS, Oosting M et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis 2011; 204 (7): 1138–45.
20. Ferwerda B, Ferwerda G, Plantinga TS et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361 (18): 1760–7.
21. Glocker E-O, Hennigs A, Nabavi M et al. A Homozygous CARD9 Mutation in a Family with Susceptibility to Fungal Infections. N Engl J Med 2009; 361 (18): 1727–35.
22. Nahum A. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. Autoimmun Rev 2012; 11 (5): 341–7.
23. Nahum A, Bates A, Sharfe N, Roifman CM. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 122 (6): 1220–2.
24. Brouwer N, Dolman KM, van Houdt M et al. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol 2008; 180 (6): 4124–32.
25. Neth O, Jack DL, Dodds AW et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68 (2): 688–93.
26. Sharfe N, Shahar M, Roifman CM. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. J Clin Investig 1997; 100 (12): 3036–43.
27. Practice Bulletin Clinical Management Guidelines for Obstetrician – Gynecologists. Obstet Gynecol 2009; 106: 192–202..
28. Mendling W. Guideline: Vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015; 58 (S1): 1–15.
29. Plantinga TS, Johnson MD, Scott WK et al. Human genetic susceptibility to Candida infections. Med Mycol 2012; 1–10.
30. Wójtowicz A, Tissot F, Lamoth F et al. Polymorphisms in tumor necrosis factor-a increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients. Crit Care Med 2014; 42 (4): e304–8.
31. Ouederni M, Sanal O, Ikincioqullari A et al. Clinical features of candidiasis in patients with inherited interleukin 12 receptor b1 deficiency. Clin Infect Dis 2014; 58 (2): 204–13.
32. Naglik JR. Candida Immunity. New J Sci 2014; 2014 (Article ID 390241).
33. Choi EH, Foster CB, Taylor JG et al. Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J Infect Dis 2003; 187 (7): 1153–6.
34. Corbett JA, Kwon G, Turk J, McDaniel ML. IL-1b induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of langerhans: Activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32 (50): 13767–70.
35. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nature reviews. Microbiology 2004; 2 (10): 820–32.
36. Johnson MD, Plantinga TS, Van De Vosse E et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: A prospective cohort study. Clin Infect Dis 2012; 54 (4): 502–10.
37. Rosentul DC, Delsing CE, Jaeger M et al. Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Front Microbiol 2014; 5: 483.
38. Sun R, Tian W, Xing X. Association of cytokine gene polymorphisms with susceptibility to invasive candidiasis. Genet Mol Res 2015; 14 (142): 6859–64.
2. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178 (2): 203–11.
3. Foxman B, Muraglia R, Dietz J-P et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Lower Genital Tract Dis 2013; 17 (3): 340–5.
4. Sobel JD. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178 (2): 203–11.
5. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016; 214 (1): 15–21.
6. Guzel AB, Ilkit M, Burgut R et al. An Evaluation of Risk Factors in Pregnant Women with Candida Vaginitis and the Diagnostic Value of Simultaneous Vaginal and Rectal Sampling. Mycopathologia 2011; 172 (1): 25–36.
7. Mårdh P-A, Rodrigues AG, Genç M et al. Facts and myths on recurrent vulvovaginal candidosis – a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002; 13 (8): 522–39.
8. Calderon L, Williams R, Martinez M et al. Genetic susceptibility to vaginal candidiasis. Med Mycol 2003; 41 (2): 143–7.
9. Jaeger M, Plantinga TS, Joosten LAB et al. Genetic basis for recurrent vulvo-vaginal candidiasis. Cur Infect Dis Rep 2013; 15 (2): 136–42.
10. Smeekens SP. Genetic susceptibility to Candida infections. EMBO Mol Med 2013; 5 (6): 805–13.
11. Rosentul D. Polymorphism in innate immunity genes and susceptibility to recurrent vulvovaginal candidiasis. J Mycol Med 2009; 19 (3): 191–6.
12. Puel A. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012; 12 (6): 616–22.
13. Babula O, Lazdane G, Kroica J et al. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37 (5): 733–7.
14. Babula O, Lazdane G, Kroica J et al. Frequency of interleukin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40 (9): 1258–62.
15. De Luca A, Carvalho A, Cunha C et al. IL-22 and IDO1 Affect Immunity and Tolerance to Murine and Human Vaginal Candidiasis. PLoS Pathogens 2013; 9 (7).
16. Donders GGG, Babula O, Bellen G et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115 (10): 1225–31.
17. Giraldo PC, Babula O, Goncalves AK et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007; 109: 1123–8.
18. Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92 (1): 43–7.
19. Rosentul DC, Plantinga TS, Oosting M et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis 2011; 204 (7): 1138–45.
20. Ferwerda B, Ferwerda G, Plantinga TS et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361 (18): 1760–7.
21. Glocker E-O, Hennigs A, Nabavi M et al. A Homozygous CARD9 Mutation in a Family with Susceptibility to Fungal Infections. N Engl J Med 2009; 361 (18): 1727–35.
22. Nahum A. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. Autoimmun Rev 2012; 11 (5): 341–7.
23. Nahum A, Bates A, Sharfe N, Roifman CM. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 122 (6): 1220–2.
24. Brouwer N, Dolman KM, van Houdt M et al. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol 2008; 180 (6): 4124–32.
25. Neth O, Jack DL, Dodds AW et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68 (2): 688–93.
26. Sharfe N, Shahar M, Roifman CM. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. J Clin Investig 1997; 100 (12): 3036–43.
27. Practice Bulletin Clinical Management Guidelines for Obstetrician – Gynecologists. Obstet Gynecol 2009; 106: 192–202..
28. Mendling W. Guideline: Vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015; 58 (S1): 1–15.
29. Plantinga TS, Johnson MD, Scott WK et al. Human genetic susceptibility to Candida infections. Med Mycol 2012; 1–10.
30. Wójtowicz A, Tissot F, Lamoth F et al. Polymorphisms in tumor necrosis factor-a increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients. Crit Care Med 2014; 42 (4): e304–8.
31. Ouederni M, Sanal O, Ikincioqullari A et al. Clinical features of candidiasis in patients with inherited interleukin 12 receptor b1 deficiency. Clin Infect Dis 2014; 58 (2): 204–13.
32. Naglik JR. Candida Immunity. New J Sci 2014; 2014 (Article ID 390241).
33. Choi EH, Foster CB, Taylor JG et al. Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J Infect Dis 2003; 187 (7): 1153–6.
34. Corbett JA, Kwon G, Turk J, McDaniel ML. IL-1b induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of langerhans: Activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32 (50): 13767–70.
35. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nature reviews. Microbiology 2004; 2 (10): 820–32.
36. Johnson MD, Plantinga TS, Van De Vosse E et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: A prospective cohort study. Clin Infect Dis 2012; 54 (4): 502–10.
37. Rosentul DC, Delsing CE, Jaeger M et al. Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Front Microbiol 2014; 5: 483.
38. Sun R, Tian W, Xing X. Association of cytokine gene polymorphisms with susceptibility to invasive candidiasis. Genet Mol Res 2015; 14 (142): 6859–64.
________________________________________________
2. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178 (2): 203–11.
3. Foxman B, Muraglia R, Dietz J-P et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Lower Genital Tract Dis 2013; 17 (3): 340–5.
4. Sobel JD. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178 (2): 203–11.
5. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016; 214 (1): 15–21.
6. Guzel AB, Ilkit M, Burgut R et al. An Evaluation of Risk Factors in Pregnant Women with Candida Vaginitis and the Diagnostic Value of Simultaneous Vaginal and Rectal Sampling. Mycopathologia 2011; 172 (1): 25–36.
7. Mårdh P-A, Rodrigues AG, Genç M et al. Facts and myths on recurrent vulvovaginal candidosis – a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002; 13 (8): 522–39.
8. Calderon L, Williams R, Martinez M et al. Genetic susceptibility to vaginal candidiasis. Med Mycol 2003; 41 (2): 143–7.
9. Jaeger M, Plantinga TS, Joosten LAB et al. Genetic basis for recurrent vulvo-vaginal candidiasis. Cur Infect Dis Rep 2013; 15 (2): 136–42.
10. Smeekens SP. Genetic susceptibility to Candida infections. EMBO Mol Med 2013; 5 (6): 805–13.
11. Rosentul D. Polymorphism in innate immunity genes and susceptibility to recurrent vulvovaginal candidiasis. J Mycol Med 2009; 19 (3): 191–6.
12. Puel A. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012; 12 (6): 616–22.
13. Babula O, Lazdane G, Kroica J et al. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37 (5): 733–7.
14. Babula O, Lazdane G, Kroica J et al. Frequency of interleukin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40 (9): 1258–62.
15. De Luca A, Carvalho A, Cunha C et al. IL-22 and IDO1 Affect Immunity and Tolerance to Murine and Human Vaginal Candidiasis. PLoS Pathogens 2013; 9 (7).
16. Donders GGG, Babula O, Bellen G et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115 (10): 1225–31.
17. Giraldo PC, Babula O, Goncalves AK et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007; 109: 1123–8.
18. Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92 (1): 43–7.
19. Rosentul DC, Plantinga TS, Oosting M et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis 2011; 204 (7): 1138–45.
20. Ferwerda B, Ferwerda G, Plantinga TS et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361 (18): 1760–7.
21. Glocker E-O, Hennigs A, Nabavi M et al. A Homozygous CARD9 Mutation in a Family with Susceptibility to Fungal Infections. N Engl J Med 2009; 361 (18): 1727–35.
22. Nahum A. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. Autoimmun Rev 2012; 11 (5): 341–7.
23. Nahum A, Bates A, Sharfe N, Roifman CM. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 122 (6): 1220–2.
24. Brouwer N, Dolman KM, van Houdt M et al. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol 2008; 180 (6): 4124–32.
25. Neth O, Jack DL, Dodds AW et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68 (2): 688–93.
26. Sharfe N, Shahar M, Roifman CM. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. J Clin Investig 1997; 100 (12): 3036–43.
27. Practice Bulletin Clinical Management Guidelines for Obstetrician – Gynecologists. Obstet Gynecol 2009; 106: 192–202..
28. Mendling W. Guideline: Vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015; 58 (S1): 1–15.
29. Plantinga TS, Johnson MD, Scott WK et al. Human genetic susceptibility to Candida infections. Med Mycol 2012; 1–10.
30. Wójtowicz A, Tissot F, Lamoth F et al. Polymorphisms in tumor necrosis factor-a increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients. Crit Care Med 2014; 42 (4): e304–8.
31. Ouederni M, Sanal O, Ikincioqullari A et al. Clinical features of candidiasis in patients with inherited interleukin 12 receptor b1 deficiency. Clin Infect Dis 2014; 58 (2): 204–13.
32. Naglik JR. Candida Immunity. New J Sci 2014; 2014 (Article ID 390241).
33. Choi EH, Foster CB, Taylor JG et al. Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J Infect Dis 2003; 187 (7): 1153–6.
34. Corbett JA, Kwon G, Turk J, McDaniel ML. IL-1b induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of langerhans: Activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32 (50): 13767–70.
35. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nature reviews. Microbiology 2004; 2 (10): 820–32.
36. Johnson MD, Plantinga TS, Van De Vosse E et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: A prospective cohort study. Clin Infect Dis 2012; 54 (4): 502–10.
37. Rosentul DC, Delsing CE, Jaeger M et al. Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Front Microbiol 2014; 5: 483.
38. Sun R, Tian W, Xing X. Association of cytokine gene polymorphisms with susceptibility to invasive candidiasis. Genet Mol Res 2015; 14 (142): 6859–64.
Авторы
Ш.М.Погосян*, Е.А.Межевитинова, А.Е.Донников, В.Н.Прилепская, О.В.Бурменская, О.С.Непша, А.А.Быстрицкий
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова» Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*shaqpoxos@mail.r
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
*shaqpoxos@mail.r
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова» Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*shaqpoxos@mail.r
________________________________________________
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
*shaqpoxos@mail.r
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.